Bicycle Therapeutics to Host R&D Day on December 14

Rhea-AI Summary

Bicycle Therapeutics plc (NASDAQ:BCYC) will host its first Research and Development (R&D) Day on December 14. The event will feature an overview of the company’s R&D strategy, pipeline opportunities, and clinical updates for BT8009, BT5528, and BT7480. Executives will also highlight the capabilities of its Bicycle® platform technology.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle^®) technology, today announced that the company will host its first Research and Development (R&D) Day on Thursday, December 14. The event will take place in New York City from 8 a.m. to 12 p.m. Eastern Time and will be simultaneously webcast.

Bicycle Therapeutics executives will provide investors and analysts with an overview of the company’s R&D strategy and pipeline opportunities, with an emphasis on clinical updates for BT8009, BT5528 and BT7480. The company will also highlight the broad capabilities of its novel Bicycle^® platform technology.

Analysts and investors who are interested in attending in person should contact bicycle@argotpartners.com. A live webcast of the R&D Day will be accessible from the Investor section of the company’s website, www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.

About Bicycle Therapeutics 
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. The company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC™) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase 1/2 trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in a Phase 1/2a clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231130298942/en/

Investors:

Stephanie Yao

SVP, Investor Relations and Corporate Communications

ir@bicycletx.com

857-523-8544

Media:

Argot Partners

Sarah Sutton

media@bicycletx.com

212-600-1902

Source: Bicycle Therapeutics

FAQ

When will Bicycle Therapeutics plc host its first Research and Development (R&D) Day?

Bicycle Therapeutics plc will host its first R&D Day on Thursday, December 14.

What will be the focus of the R&D Day?

The R&D Day will feature an overview of the company’s R&D strategy, pipeline opportunities, and clinical updates for BT8009, BT5528, and BT7480.

Where will the event take place?

The event will take place in New York City.

How can interested individuals attend the event?

Analysts and investors who are interested in attending in person should contact bicycle@argotpartners.com. A live webcast of the R&D Day will be accessible from the Investor section of the company’s website, www.bicycletherapeutics.com.

Will the webcast be available for replay?

Yes, a replay of the webcast will be archived and available following the event.